The estimated Net Worth of Corwin Dale Hooks is at least $215 Tisíc dollars as of 15 June 2018. Corwin Hooks owns over 939 units of Applied Therapeutics stock worth over $8,310 and over the last 9 years Corwin sold APLT stock worth over $206,870.
Corwin has made over 2 trades of the Applied Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently Corwin sold 939 units of APLT stock worth $42,696 on 15 June 2018.
The largest trade Corwin's ever made was selling 2,150 units of Applied Therapeutics stock on 31 August 2017 worth over $164,174. On average, Corwin trades about 172 units every 16 days since 2016. As of 15 June 2018 Corwin still owns at least 1,595 units of Applied Therapeutics stock.
You can see the complete history of Corwin Hooks stock trades at the bottom of the page.
Corwin's mailing address filed with the SEC is 5500 Flatiron Pkwy, Boulder, CO 80301, USA.
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus a Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: